scispace - formally typeset
Z

Zhuo-Xun Wu

Researcher at St. John's University

Publications -  51
Citations -  971

Zhuo-Xun Wu is an academic researcher from St. John's University. The author has contributed to research in topics: Multiple drug resistance & Biology. The author has an hindex of 12, co-authored 32 publications receiving 329 citations.

Papers
More filters
Journal ArticleDOI

Microbiota in health and diseases

TL;DR: The role of microbiota in health and diseases is highlighted by numerous studies since its discovery as mentioned in this paper , which can lead to dysregulation of bodily functions and diseases including cardiovascular diseases (CVDs), cancers, respiratory diseases, etc.
Journal ArticleDOI

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

TL;DR: The reversal of the dual functions of ABC-transporter-mediated and AKT-activation-enhanced MDR through the inhibition or knockout of PI3K 110α or 110β promises to improve current strategies based on combined drug treatments to overcome MDR challenges.
Journal ArticleDOI

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.

TL;DR: The recent progress in overcoming cancer drug resistance is summarized in three novel aspects: mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation, and posttranslational modification on molecules, which encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis.
Journal ArticleDOI

Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.

TL;DR: The applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed.
Journal ArticleDOI

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

TL;DR: A potential chemotherapeutic strategy of co-administrating tepotinib with other conventional chemotherAPEutic agents to overcome MDR and improve therapeutic effect is provided.